Federal Panel to Consider AndroGel Lawsuit Consolidation, Bernstein Liebhard LLP Reports

May 13, 2014, 11:43 ET from Bernstein Liebhard LLP

NEW YORK, May 13, 2014 /PRNewswire/ -- Later this month, a panel of federal judges will consider a proposal to establish a multidistrict litigation for all federally-filed AndroGel lawsuits (http://www.testosteronelawsuitcenter.com/androgel-lawsuit/)  that allege the testosterone medication caused patients to suffer heart attacks, strokes and other cardiovascular injuries, Bernstein Liebhard LLP reports. According to a Notice of Hearing Session issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on April 14th, 2014, the Panel will hear Oral Arguments on the matter during a May 29th hearing in Chicago, Illinois. Plaintiffs who have filed testosterone treatment lawsuits involving AndroGel have requested that the federal cases be consolidated and transferred to the U.S. District Court, Northern District of Illinois, for coordinated pretrial proceedings. (In Re: AndroGel Product Liability Litigation, No. 2545, JPML)

"Our Firm has heard from numerous men who allegedly suffered life-threatening heart problems due to their use of drugs like AndroGel. The consolidation of AndroGel lawsuits in a single federal court would likely allow the cases to proceed more efficiently," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free testosterone lawsuit reviews to anyone who may have suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious heart problems allegedly due to the use of prescription testosterone therapies.

Testosterone Treatment Lawsuits

Court documents indicate that 85 testosterone treatment lawsuits involving AndroGel and similar medications are currently pending in federal courts around the country. In response to the plaintiffs' request for the establishment of a multidistrict litigation for all federally-filed AndroGel claims, some drug manufacturers, including AbbVie, Inc., Abbott Laboratories, Eli Lilly and Co., Lilly USA, LLC, have asserted that the proceeding should include all federal testosterone lawsuits, regardless of medications involved, because many cases are likely to include claims against multiple manufacturers.

Low testosterone therapies are indicated for the treatment of hypogonadism (low testosterone) in men who suffer from the disorder due to an underlying illness or injury. In addition to AndroGel, other drugs in this class include:

  • Axiron
  • AndroDerm
  • AndroGel
  • Bio-T Gel
  • Delatestryl
  • Depo-Testosterone
  • Foresta
  • Striant
  • Testopel
  • Testim

Testosterone treatment lawsuits involving these medications have been mounting since January 31, 2014, when the U.S. Food & Drug Administration (FDA) revealed that it was reviewing a number of studies that indicated that low testosterone therapy may increase the risk for heart attacks, strokes and death in certain men.

Men who may have suffered heart attacks, strokes, or other heart problems, allegedly due to low testosterone therapies like AndroGel may be eligible to file their own testosterone treatment lawsuit. To find out more  about this growing litigation, please visit Bernstein Liebhard LLP's website, or call (888) 340-4807 for a free legal consultation.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney's fees unless their case results in a successful recovery on their behalf. New York State's contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm's fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff's recovery.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:  
Felecia L. Stern, Esq. 
Bernstein Liebhard LLP 
info (at) consumerinjurylawyers (dot) com 

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

SOURCE Bernstein Liebhard LLP